Segment Information (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended March 31, 2022 and 2021 is as follows:

	Three Months Ended March 31, 2022
	Cell Therapy			BioBanking			Degenerative Disease		Other				Total
Net sales	$	-		$	1,283		$	4,652	$	-			$	5,935
Gross profit		-			335			1,574		-				1,909
Direct expenses		21,213			626			1,459		13,270				36,568
Segment contribution		(21,213	)		(291	)		115		(13,270	)			(34,659	)
Indirect expenses										6,955		(c)		6,955
Loss from operations													$	(41,614	)
(c) Components of other
Change in fair value of contingent consideration liability										4,849
Change in fair value of contingent stock consideration										1,565
Amortization										541
Total other									$	6,955

	Three Months Ended March 31, 2021
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	-		$	1,264	$	1,396		$	-			$	2,660
Gross profit		-			540		878			-				1,418
Direct expenses		16,287			252		2,014			6,063				24,616
Segment contribution		(16,287	)		288		(1,136	)		(6,063	)			(23,198	)
Indirect expenses										21,197		(d)		21,197
Loss from operations													$	(44,395	)
(d) Components of other
Change in fair value of contingent consideration liability										20,656
Impairment of acquired intangible assets										-
Amortization										541
Total other									$	21,197